Modification to:fastix Thc/Coc Drug Screen Dipstick Test, Fastix Thc/Coc/Met Drug Screen Dipstick Test, Fastix Opi/Met
510(k) K012541
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK012541 | Date4 Sep 2001 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- LDJ
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3870
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 19 Sep 2026
This device is an enzyme immunoassay for qualitative detection of cannabinoids, opioids, and methadone metabolites in urine specimens. It functions as a rapid, point-of-care test to screen for the presence of these substances, aiding in clinical toxicology assessments.
The Fastix tests are single-use, non-sterile dipstick devices intended for use in clinical laboratory settings or point-of-care environments. They are classified as Class II devices under FDA regulations and require compliance with 21 CFR Part 820 for manufacturing and quality systems. Each test kit includes pre-packaged dipsticks with specific lot numbers for traceability and is authorized under FDA 510(k) clearance (K012541)
Other devices from Branan Medical Corp.
Questions
AI-generated answers, 19 Sep 2026
What substances does this test detect, and how quickly can results be obtained?
This device detects cannabinoids (THC), opioids, and methadone metabolites in urine specimens using an enzyme immunoassay. As a rapid point-of-care test, it is designed for quick screening, though the exact timeframe for results isn’t specified in the data. It’s intended for clinical toxicology assessments in settings like laboratories or point-of-care environments.
Are these dipstick tests reusable, and what is their sterility status?
The Fastix tests are explicitly labeled as single-use, non-sterile dipstick devices. Each test is pre-packaged with a unique lot number for traceability, meaning they cannot be reused after one use. Sterility is not a requirement for this application, as the device is intended for use in clinical toxicology screening.
How are these tests supplied, and what should I consider when storing them?
The tests come in pre-packaged kits, each containing dipsticks with assigned lot numbers for traceability. Storage conditions aren’t detailed in the data, but since they’re non-sterile and single-use, they should be stored in a dry, cool environment (typically 2–25°C) away from direct sunlight or extreme humidity to preserve their integrity until use. Always follow the manufacturer’s instructions for optimal performance.
What regulatory pathway was used for FDA clearance, and what does this mean for my facility?
This device received FDA 510(k) clearance (K012541) under a Special 510(k) classification, determined to be substantially equivalent to a predicate device. The clearance was granted by the FDA’s Clinical Toxicology Advisory Committee in Texas. This means your facility can legally use it for its intended purpose—qualitative detection of cannabinoids, opioids, and methadone metabolites in urine—provided you comply with FDA quality system regulations (21 CFR Part 820).